Literature DB >> 11168352

Killing cancer cells by poly-drug elevation of ceramide levels: a hypothesis whose time has come?

N S Radin1.   

Abstract

Many papers have shown that sphingolipids control the balance in cells between growth and proliferation, and cell death by apoptosis. Sphingosine-1-phosphate (Sph1P) and glucosylceramide (GlcCer) induce proliferation processes, and ceramide (Cer), a metabolic intermediate between the two, induces apoptosis. In cancers, the balance seems to have come undone and it should be possible to kill the cells by enhancing the processes that lead to ceramide accumulation. The two control systems are intertwined, modulated by a variety of agents affecting the activities of the enzymes in Cer-GlcCer-Sph1P interdependence. It is proposed that successful cancer chemotherapy requires the use of many agents to elevate ceramide levels adequately. This review updates current knowledge of sphingolipid metabolism and some of the evidence showing that ceramide plays a causal role in apoptosis induction, as well as a chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11168352     DOI: 10.1046/j.1432-1033.2001.01845.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  22 in total

Review 1.  Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.

Authors:  Thomas H Beckham; Saeed Elojeimy; Joseph C Cheng; Lorianne S Turner; Stanley R Hoffman; James S Norris; Xiang Liu
Journal:  Expert Opin Ther Targets       Date:  2010-05       Impact factor: 6.902

2.  gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis.

Authors:  Qing Jiang; Jeffrey Wong; Henrik Fyrst; Julie D Saba; Bruce N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-13       Impact factor: 11.205

3.  Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins.

Authors:  Leah J Siskind; Richard N Kolesnick; Marco Colombini
Journal:  J Biol Chem       Date:  2002-05-10       Impact factor: 5.157

4.  Trojan-horse nanotube on-command intracellular drug delivery.

Authors:  Chia-Hsuan Wu; Cong Cao; Jin Ho Kim; Chih-Hsun Hsu; Harold J Wanebo; Wayne D Bowen; Jimmy Xu; John Marshall
Journal:  Nano Lett       Date:  2012-10-25       Impact factor: 11.189

5.  Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Authors:  Kristin Gustafsson; Birgitta Sander; Jacek Bielawski; Yusuf A Hannun; Jenny Flygare
Journal:  Mol Cancer Res       Date:  2009-07       Impact factor: 5.852

6.  Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells.

Authors:  Tommer Ravid; Adili Tsaba; Peter Gee; Reuven Rasooly; Edward A Medina; Tzipora Goldkorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-02-07       Impact factor: 5.464

Review 7.  A turn in the road: How studies on the pharmacology of glucosylceramide synthase inhibitors led to the identification of a lysosomal phospholipase A2 with ceramide transacylase activity.

Authors:  James A Shayman; Akira Abe; Miki Hiraoka
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

8.  Ceramide galactosyltransferase (UGT8) is a molecular marker of breast cancer malignancy and lung metastases.

Authors:  P Dzięgiel; T Owczarek; E Plazuk; A Gomułkiewicz; M Majchrzak; M Podhorska-Okołów; K Driouch; R Lidereau; M Ugorski
Journal:  Br J Cancer       Date:  2010-07-20       Impact factor: 7.640

Review 9.  Use of liposomes as drug delivery vehicles for treatment of melanoma.

Authors:  Melissa A Tran; Rebecca J Watts; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-22       Impact factor: 4.693

10.  Enlargement and contracture of C2-ceramide channels.

Authors:  Leah J Siskind; Amirparviz Davoody; Naomi Lewin; Stephanie Marshall; Marco Colombini
Journal:  Biophys J       Date:  2003-09       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.